Format

Send to

Choose Destination
Ann Oncol. 2014 Sep;25(9):1681-90. doi: 10.1093/annonc/mdu145. Epub 2014 Apr 8.

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.

Author information

1
Department of Pathology, Aberdeen Royal Infirmary and Aberdeen University Medical School, Aberdeen, UK clinicalguidelines@esmo.org.
2
Institute for Pathology, University Hospital Basel, Basel, Switzerland.
3
University of New Mexico Cancer Center, Albuquerque, USA.
4
Center of Predictive Molecular Medicine, Center of Excellence on Ageing, University-Foundation, Chieti, Italy.
5
Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin New Territories, Hong Kong, China.
6
Thoracic Oncology Unit, Department of Oncology, University of Turin, Azienda Ospedaliero-Universitaria San Luigi Orbassano, Italy.
7
Trinity College, Dublin, Ireland Queensland University of Technology, Brisbane, Australia.
8
Clinic of Oncology, University Hospital Zürich, Zürich.
9
Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
10
Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.

Abstract

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.

KEYWORDS:

ESMO; consensus; molecular testing; non-small-cell lung cancer; pathology; recommendations

PMID:
24718890
DOI:
10.1093/annonc/mdu145
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center